...the development and evaluation of genomic and other personalized medicine approaches poses significant challenges for CER in oncology.
Ponte Vedra Beach, FL (PRWEB) May 29, 2013
This week’s top news story on HealthEconomics.Com covered newly released survey results on Payer Strategies for Emerging Markets, conducted by Hanson Wade, based on interviews with Pharma/Biotech/Medical Device companies, Consulting companies, Academia, Regulators, and Providers. There was universal consensus among the respondents that, by 2018, more than one-third of pharmaceutical company revenues will come from emerging markets, including Brazil, Russia, Asia/Pac, Africa, among others. The greatest barrier to pharma growth in emerging markets was weak industry-payer partnerships (33% of respondents), followed by lack of out-of-pocket payer engagement (22%) and competition from generics (22%). Diabetes was thought to be the biggest potential therapeutic area, while Saudia Arabia followed by Nigeria were two countries of focus after BRIC TM (Brazil, Russia, India, China, Turkey, and Mexico) emerging markets. This story was sourced from Hanson Wade Limited.
The second most read story on HealthEconomics.Com was derived from an abstract by Dr. Gary Lyman, of Duke University and the Duke Cancer Institute in Durham, North Carolina, published in The Oncologist journal on May 22, 2013 discussing comparative effectiveness research (CER) in oncology. Oncology is a therapeutic area that is uniquely positioned to utilize CER to inform appropriate and optimal patient care, particularly among high-cost interventions. The author posits that the development and evaluation of genomic and other personalized medicine approaches poses significant challenges for CER in oncology. Lyman has written on this subject in other journals, including the Journal of Clinical Oncology.
Another popular news item on HealthEconomics.Com covered the latest addition to the HE-Artist series with a profile of Sean Sullivan, PhD, Professor and Associate Dean for Research at the University of Washington School of Pharmacy who is also a drummer and plays in a band of health economists called The Monte Carlos. Dr. Sullivan’s passion for drumming, coupled with his many contributions to the field of health economics and health policy, are featured in HE-Artists on HealthEconomics.Com.
About HealthEconomics.Com (http://www.healtheconomics.com):
A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.